Reply to: Frequent selfâassessments in ALS clinical trials: Worthwhile or an unnecessary burden?
Sign Up to like & getrecommendations! Published in 2020 at "Annals of Clinical and Translational Neurology"
DOI: 10.1002/acn3.51177
Abstract: Reply to: Frequent self-assessments in ALS clinical trials: Worthwhile or an unnecessary burden? Seward B. Rutkove , Pushpa Narayanaswami, Visar Berisha, Julie Liss, Shira Hahn, Kerisa Shelton, Kristin Qi, Sarbesh Pandeya & Jeremy M. Shefner… read more here.
Keywords: frequent self; reply frequent; assessments als; clinical trials ... See more keywords
ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?
Sign Up to like & getrecommendations! Published in 2017 at "Frontiers in Aging Neuroscience"
DOI: 10.3389/fnagi.2017.00068
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality of 30,000 patients a year worldwide. The median reported survival time since onset ranges from 24 to 48 months. Riluzole is the only… read more here.
Keywords: treatment; clinical trials; masitinib; edaravone ... See more keywords
Cortical Excitability across the ALS Clinical Motor Phenotypes
Sign Up to like & getrecommendations! Published in 2021 at "Brain Sciences"
DOI: 10.3390/brainsci11060715
Abstract: Amyotrophic lateral sclerosis (ALS) is characterized by its marked clinical heterogeneity. Although the coexistence of upper and lower motor neuron signs is a common clinical feature for most patients, there is a wide range of… read more here.
Keywords: across als; motor phenotypes; cortical excitability; motor ... See more keywords